New Report from Trinity Partners Highlights Key Barriers to U.S. Biosimilar Adoption

Complex Pricing Structures, Legal and Regulatory Barriers,
and Clinical Uncertainty Hinder Progress in Biosimilar Market Access

Key findings from the report, which seeks to reveal opportunities to accelerate biosimilar adoption, include the following:

  • Biosimilar pricing to date has not offered the sharp discounts payers expect, after accounting for contract discounts and nuances such as the “rebate trap”;
  • Biologic innovators have taken legal and promotional actions that derail biosimilar commercial success;
  • Providers are not fully comfortable with biosimilars and are interested in seeing more clinical and real-world data; if biosimilars were to attain interchangeability status, this gap in clinical comfort could be minimized

The report, conducted in partnership with Schlesinger Associates, is supported by findings from qualitative market research with medical directors at payer organizations in the United States. The findings are based on historical trends, current market dynamics, and future market access expectations in biosimilars.

“Biosimilar access still lags behind traditional small molecule markets, but there is so much potential for long-term cost savings for payer plans and the U.S. healthcare system as a whole,” said Neal Dunn, Partner, Trinity Partners. “Once interchangeability is achieved, other barriers such as clinical confidence and litigation will fall into place.”

“Each country’s commercial and regulatory landscape is nuanced based on laws, pay structures, and culture, which creates unique environments for market access,” said John Corcoran, Founder and President, Trinity Partners. “Our in-depth knowledge of the U.S. market provides us with unique insights that allow us to optimally navigate those channels to achieve market access as quickly as possible, thus providing treatments to patients who need them the most.”

To view the full research report, click here.

About Trinity Partners
Trinity Partners is a trusted life sciences strategy consulting firm that takes a personalized approach to working with pharmaceutical, biotech, medical device, and diagnostic clients worldwide to create evidence-based solutions that drive business strategy and impact bottom lines. To learn more about Trinity Partners, click here.

Trinity Partners Founder and President, John Corcoran Discusses Drug Affordability in 2018

In a recent article for Managed Healthcare Executive, reporter Mari Edlin spoke with Trinity’s John Corcoran about what he sees in the pipeline for 2018 in terms of drug affordability and pharma’s response to the matter. You can read the full article including further insights from John, here: http://bit.ly/2DHZpwg

Trinity Employees Attend Disorder: Rare Disease Film Festival

Several of Trinity’s Waltham employees attended the Disorder: Rare Disease Film Festival on October 3 in Boston. The event, designed to increase awareness, connect patients and lead to new research paths, was an invaluable experience to
learn about the stories of rare disease patients around the world. Employees also enjoyed hearing from filmmakers, researchers, and patient advocates. The day was a valuable glimpse into the challenges faced by many in the rare disease community on a regular
basis and inspires us to continue helping clients address the needs of patients with rare diseases. For more information about the Disorder: Rare Disease Film Festival, please visit:
http://bit.ly/2sWDI8M.

Trinity Partners Identifies Value Proposition of Most Expensive Drugs Approved by the FDA from 2014-2016

Trinity Partners today, in tandem with the 22nd Annual International ISPOR Meeting, announced the results of a whitepaper titled, “What We Value: The Proposition Behind the Price.” The authors analyze the costliest drugs to the healthcare system approved by the FDA from 2014-2016 in order to understand the interaction between value and price.  In this industry analysis, Trinity reveals the factors that appear to allow some drugs a higher price point than others and addresses key questions including: What do the most expensive drug launches in the recent past reveal about what our society values? What does the market seem to be willing to pay for?

Download the whitepaper here: http://bit.ly/2qQyKso

Trinity Partners Supports Rare Disease Day Around the Country

Trinity Partners honored Rare Disease Day on February 28th, a day dedicated to raising awareness amongst the general public and decision-makers about rare diseases and their impact on patients’ lives. We attended several events throughout the country, including MassBio’s Patient Advocacy meeting at the Massachusetts State House and the Metropolitan Hospital Center’s Rare Disease event in New York City. We also tuned into MassBio and ABC News’ Rare Disease Day Tweetchat. Check out a few pictures of our team advocating for the rare disease community!

Trinity Partners Identifies Hallmarks of Successful US Biopharma M&As

Trinity Partners today, in concert with the 35th Annual JP Morgan Healthcare Conference, has announced the findings of a white paper exploring the strategic decisions that successfully position a company for a maximized M&A exit. By examining the past ten years of biopharma M&A activity, Trinity has developed a framework that summaries the optimal path for private companies, taking into consideration major factors that inform valuations including financials, R&D portfolio, licensing opportunities, partnerships and more.

 

Download the whitepaper HERE